{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:08:06Z","timestamp":1761516486939,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.4158\/ep171829.co","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T17:08:54Z","timestamp":1493312934000},"page":"745-746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anabolic Bone Window with Weekly Teriparatide Therapy in Postmenopausal Osteoporosis"],"prefix":"10.1016","volume":"23","author":[{"given":"Ejigayehu G.","family":"Abate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP171829.CO_bb0010","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171829.CO_bb0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/EP171829.CO_bb0020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fendo.2016.00172","article-title":"Review of hypoparathyroidism","volume":"7","author":"Abate","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.4158\/EP171829.CO_bb0025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs. placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.4158\/EP171829.CO_bb0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s001980050151","article-title":"Effect of an intermittent weekly dose of human parathyroid hormone (1\u201334) on osteoporosis: a randomized double-masked prospective study using three dose levels","volume":"9","author":"Fujita","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171829.CO_bb0035","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized Teriparatide [human parathyroid hormone (PTH) 1\u201334] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP171829.CO_bb0040","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00198-013-2516-1","article-title":"Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis","volume":"25","author":"Sugimoto","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171829.CO_bb0045","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4158\/EP161394.OR","article-title":"Anabolic window with weekly teriparatide therapy in postmenopausal osteoporosis: a pilot study","volume":"23","author":"Gopalaswamy","year":"2017","journal-title":"Endocr Pract"},{"key":"10.4158\/EP171829.CO_bb0050","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"10.4158\/EP171829.CO_bb0055","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20358122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20358122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:02:46Z","timestamp":1761516166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20358122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1530891X20358122"],"URL":"https:\/\/doi.org\/10.4158\/ep171829.co","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anabolic Bone Window with Weekly Teriparatide Therapy in Postmenopausal Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP171829.CO","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}